Organization
Eberhard Karls University of Tübingen
3 abstracts
Abstract
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.Org: Vanderbilt-Ingram Cancer Center, Russian Scientific Center of Roentgenoradiology, Central Clinical Hospital With Outpatient Clinic, Centre Hospitalier de l’Université de Montréal, Hospital de Clínicas de Porto Alegre,
Abstract
N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.Org: University of Heidelberg, NCT Heidelberg, Heidelberg University Hospital, Department of Neurology and Hematology-Oncology, Department of Neuroradiology,
Abstract
Interim analysis of MelaRisk, a biomarker assay validation study in stage IB/IIA melanoma tissue.Org: Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany, Tübingen, Germany,